# Perspectum Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/perspectum-diagnostics

- Industry: Software
- Headquarters: Oxford, UK
- Website: www.perspectum.com
- Total disclosed funding: $35M
- Latest round: Series B (Apr 1, 2020)
- Investors on record: 5

## About

Based in the UK, Perspectum Diagnostics Ltd focuses on advanced imaging technology to improve diagnostic accuracy and patient care through innovative solutions like CoverScan, targeted at various health conditions.Perspectum Diagnostics Ltd, founded in 2012 in Oxford, UK, specializes in enhancing diagnostic imaging for healthcare. The company has undergone strategic pivots to expand its offerings and is led by CEO Rajarshi Banerjee. Notably, Matthew Robson, the founder, has a history of entrepreneurship, although details of other ventures are not provided. The company has engaged in nine deals, with the latest funding round being a Series C, where they raised USD 19 mn on February 14, 2023, led by Oppenheimer, bringing total capital raised to USD 19 mn with a current valuation of USD 278.63 mn.Perspectum specializes in advanced imaging solutions designed to enhance diagnostic capabilities and personalize patient care. Central to their offerings is CoverScan, a multi-organ MRI technology that extracts biomarkers from imaging data, providing healthcare professionals with a comprehensive view of a patient's health. This innovative approach allows for more nuanced insights compared to traditional one-dimensional diagnostics, thereby facilitating improved decision-making and treatment personalization. The company’s solutions are employed across various healthcare settings, targeting conditions such as liver disease, cancer, and diabetes, ultimately focusing on enhancing patient outcomes. Perspectum's products are utilized in multiple geographical markets, including North America and Europe, with partnerships established with healthcare providers, research institutions, and pharmaceutical companies to broaden their impact.For the fiscal year 2023, Perspectum reported revenue of USD 23,837,343.60 with an EBITDA of -USD 19,488,684.50. The company's revenue model primarily revolves around B2B transactions, where they collaborate with healthcare providers and research organizations to deliver imaging solutions, often through subscription agreements that ensure ongoing support and updates.In February 2023, Perspectum Diagnostics Ltd raised USD 19 mn in Series C funding, part of a larger USD 55 mn financing round, which will be used to scale operations in the US and to accelerate the development of products targeting multiorgan conditions and oncology. The company is focusing on expanding its reach into new markets, particularly within North America, to enhance its impact on healthcare. They aim to launch new products designed to further improve diagnostic capabilities, aligning with their growth strategy.

## Funding rounds

- Series B, Apr 1, 2020, $35M — BlueCross BlueShield Venture Partners, University of Oxford, HealthQuest Capital, Oxford Sciences Enterprises, Puhua Capital

## Investors

- BlueCross BlueShield Venture Partners (https://capitalatlas.ai/funds/bluecross-blueshield-venture-partners) — Series B
- University of Oxford — Series B
- HealthQuest Capital (https://capitalatlas.ai/funds/healthquest-capital) — Series B
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series B
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series B